Phase4 Ventures is a leading venture capital firm based in London that invests in development stage life science companies in the US and Europe. Founded in 1999, the team has made close to 30 investments in Life Science companies alongside other top tier venture capital firms in both Europe and the US. The team is complemented by an extensive group of advisors with operating experience at a senior level in pharmaceutical and biotechnology companies. Phase4 Ventures' investments include many of the companies that have provided successful European and US venture exits including Intercell, Pharmion, Targacept and most recently Proteolix.
Phase4 Ventures was spun-out from Nomura in December 2010 following a buy out of the management company by the team and a secondary purchase of a fund by HarbourVest Partners. Phase4 Ventures currently manages funds for both Nomura and HarbourVest.
Phase4 Ventures Limited is a member of the British Private Equity and Venture Capital Association (BVCA) and the European Private Equity and Venture Capital Association (EVCA).